ECSP003836A - Composicion estable para dosis oral de liberacion extendida - Google Patents

Composicion estable para dosis oral de liberacion extendida

Info

Publication number
ECSP003836A
ECSP003836A EC2000003836A ECSP003836A ECSP003836A EC SP003836 A ECSP003836 A EC SP003836A EC 2000003836 A EC2000003836 A EC 2000003836A EC SP003836 A ECSP003836 A EC SP003836A EC SP003836 A ECSP003836 A EC SP003836A
Authority
EC
Ecuador
Prior art keywords
hours
extended release
pseudoephedrine
stable composition
composition
Prior art date
Application number
EC2000003836A
Other languages
English (en)
Inventor
Jim H Kou
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP003836(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP003836A publication Critical patent/ECSP003836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)

Abstract

Se describe una composición para dosis oral sólida de liberación extendida revestida con una película que contiene un descongestivo nasal, pseudoefedrina, o su sal por ejemplo, sulfato de pseudoefedrina en un núcleo efectivo como proporcionar una concentración en plasma máxima geométrica de pseudoefedrina entre alrededor de 345 ng/ml en un tiempo entre alrededor de 7,60 horas y alrededor de 8,40 horas y que tiene dos o tres revestimientos de película sobre el núcleo, el segundo contiene una cantidad de antihistamina, no sedativa, desloratadina, efectiva como para proporcionar una concentración en plasma máximo geométrica de desloratadina entre alrededor de 2,15 ng/ml y alrededor de 2,45 ng/ml en un tiempo entre alrededor de 4,0 horas y alrededor de 4,5 horas, y el uso de la composición para tratar pacientes que muestran signos y síntomas asociadas con las condiciones alérgicas y/o inflamatorias de la piel y de las vías aéreas.
EC2000003836A 1999-12-20 2000-12-20 Composicion estable para dosis oral de liberacion extendida ECSP003836A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (1)

Publication Number Publication Date
ECSP003836A true ECSP003836A (es) 2002-02-25

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003836A ECSP003836A (es) 1999-12-20 2000-12-20 Composicion estable para dosis oral de liberacion extendida

Country Status (37)

Country Link
US (2) US6979463B2 (es)
EP (2) EP2196195A3 (es)
JP (3) JP5042403B2 (es)
KR (2) KR100936572B1 (es)
CN (3) CN1679569A (es)
AR (1) AR027033A1 (es)
AT (1) ATE463240T1 (es)
AU (4) AU2277101A (es)
BR (1) BR0006403A (es)
CA (1) CA2329217C (es)
CO (1) CO5251435A1 (es)
CY (1) CY1110693T1 (es)
CZ (1) CZ302860B6 (es)
DE (1) DE60044117D1 (es)
DK (1) DK1112738T3 (es)
EC (1) ECSP003836A (es)
EG (1) EG23759A (es)
ES (1) ES2341751T3 (es)
HU (1) HUP0004988A3 (es)
ID (1) ID28675A (es)
IL (1) IL140450A (es)
MX (1) MXPA00013037A (es)
MY (1) MY130773A (es)
NO (1) NO331645B1 (es)
NZ (1) NZ509028A (es)
PE (1) PE20010982A1 (es)
PL (1) PL211573B1 (es)
PT (1) PT1112738E (es)
RU (2) RU2303440C2 (es)
SA (2) SA01210741B1 (es)
SG (1) SG109438A1 (es)
SI (1) SI1112738T1 (es)
SK (1) SK287684B6 (es)
TR (1) TR200003787A2 (es)
TW (1) TWI225414B (es)
WO (1) WO2001045668A2 (es)
ZA (1) ZA200007715B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1700591A4 (en) * 2003-12-01 2011-08-03 Takeda Pharmaceutical METHOD FOR THE TREATMENT OF A SOLID PHARMACEUTICAL PREPARATION BEFORE PRINTING AND PRESTIGIOUS SOLENOID PREPARATION TREATED BEFORE PRINTING
WO2006047427A1 (en) * 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080210748A1 (en) 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
RU2008151945A (ru) * 2006-06-01 2010-07-20 Шеринг Корпорейшн (US) Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина
WO2007143163A2 (en) * 2006-06-01 2007-12-13 Schering Corporation Pharmaceutical compositions for sustained release of phenyephrine
WO2007143158A2 (en) * 2006-06-01 2007-12-13 Schering-Plough Healthcare Products, Inc. Sustained release pharmaceutical formulation comprising phenylephrine
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
CN101848706A (zh) * 2007-06-01 2010-09-29 先灵-普劳健康护理产品公司 包含底物和含活性成分和聚乙烯醇的包衣的药用组合物
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) * 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
CR20230109A (es) 2020-07-30 2023-05-11 Faes Farma Sa Sistema de liberación de fármacos descongestivos y bilastina

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
HU194864B (en) 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) * 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
IE68935B1 (en) 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
WO1992011034A1 (en) 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
CO4910128A1 (es) * 1996-10-31 2000-04-24 Schering Corp Tratamiento del asma y compuestos utiles para este trata- miento ta combinacion y un kit de esta combinacion
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) * 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
AU1205799A (en) * 1997-10-29 1999-05-17 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
CA2325014C (en) 1998-07-10 2002-05-28 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6051585A (en) * 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
HK1046367A1 (zh) * 2000-02-03 2003-01-10 Schering Corporation 治疗过敏和炎症症状
AU5722701A (en) * 2000-05-19 2001-12-03 Alcon Universal Ltd Aniline disulfide derivatives for treating allergic diseases
US6599913B1 (en) * 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
SI1112738T1 (sl) 2010-07-30
JP2008081510A (ja) 2008-04-10
PE20010982A1 (es) 2001-09-28
US20060159761A1 (en) 2006-07-20
EP1112738A2 (en) 2001-07-04
SA06270069B1 (ar) 2009-06-07
CN1679569A (zh) 2005-10-12
AU781924B2 (en) 2005-06-23
CY1110693T1 (el) 2015-06-10
EP1112738B1 (en) 2010-04-07
HK1034453A1 (en) 2001-10-26
WO2001045668A2 (en) 2001-06-28
HU0004988D0 (es) 2001-02-28
NO20006504D0 (no) 2000-12-20
RU2007104095A (ru) 2008-08-10
CZ20004812A3 (cs) 2001-08-15
KR20010062542A (ko) 2001-07-07
EP1112738A3 (en) 2001-07-18
ZA200007715B (en) 2001-06-20
DK1112738T3 (da) 2010-06-28
EG23759A (en) 2007-08-08
CN101081224B (zh) 2012-05-30
AU7244300A (en) 2001-06-21
RU2303440C2 (ru) 2007-07-27
NO331645B1 (no) 2012-02-13
RU2423106C9 (ru) 2012-06-27
PL211573B1 (pl) 2012-05-31
TR200003787A3 (tr) 2001-07-23
NO20006504L (no) 2001-06-21
AU2009200460B2 (en) 2012-01-19
CN1301534A (zh) 2001-07-04
SA01210741A (ar) 2005-12-03
DE60044117D1 (de) 2010-05-20
EP2196195A3 (en) 2012-02-29
AU2005203771A1 (en) 2005-09-15
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
SA01210741B1 (ar) 2006-10-31
EP2196195A2 (en) 2010-06-16
CZ302860B6 (cs) 2011-12-21
PL344715A1 (en) 2001-07-02
JP2012224642A (ja) 2012-11-15
CN1211079C (zh) 2005-07-20
SK19672000A3 (sk) 2001-09-11
JP5042403B2 (ja) 2012-10-03
CA2329217A1 (en) 2001-06-20
MXPA00013037A (es) 2003-06-19
NZ509028A (en) 2002-12-20
JP2001172174A (ja) 2001-06-26
TR200003787A2 (tr) 2001-07-23
IL140450A0 (en) 2002-02-10
ID28675A (id) 2001-06-21
WO2001045668A3 (en) 2001-12-13
IL140450A (en) 2011-11-30
AU2277101A (en) 2001-07-03
RU2423106C2 (ru) 2011-07-10
KR20110028326A (ko) 2011-03-17
TWI225414B (en) 2004-12-21
ATE463240T1 (de) 2010-04-15
HUP0004988A3 (en) 2008-04-28
AU2009200460A1 (en) 2009-02-26
AR027033A1 (es) 2003-03-12
KR101234940B1 (ko) 2013-02-19
KR100936572B1 (ko) 2010-01-13
SG109438A1 (en) 2005-03-30
PT1112738E (pt) 2010-06-04
BR0006403A (pt) 2001-07-17
MY130773A (en) 2007-07-31
CA2329217C (en) 2006-10-31
US7820199B2 (en) 2010-10-26
SK287684B6 (sk) 2011-06-06
HUP0004988A2 (hu) 2002-11-28
CN101081224A (zh) 2007-12-05
CO5251435A1 (es) 2003-02-28
ES2341751T3 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
ECSP003836A (es) Composicion estable para dosis oral de liberacion extendida
ES2110633T3 (es) Composicion estable de dosificacion oral de liberacion prolongada.
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
ES2185817T3 (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato.
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
BR9806470A (pt) Preparação do tipo absorção percutânea.
BR0116972A (pt) Métodos e dispositivos para administração de substâncias na camada intradérmica da pele para absorção sistêmica
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
BR0308795A (pt) Amidas do ácido sulfamico
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
AR014082A1 (es) Concentrado oral de sertralina
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
AR083893A1 (es) Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
ES2182524T3 (es) Composiciones de hidroxiomeprazol y sus utilizaciones.
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
MX9306005A (es) Combinaciones de ibupropeno-cafeina.
PT927031E (pt) Composicao farmaceutica que contem nimesulide para administracao por via oral